About VCaP-MDVR
Ideal for: Anti-androgen drug resistance studies, castration resistant studies
Most late-stage prostate cancer patients receiving next-generation anti-androgens initially respond to treatment, but this is usually followed by inevitable disease progression. Therefore, discovery of drugs that overcome adaptive resistance mechanisms is paramount. VCaP is a desirable prostate cancer cell line for in vivo studies as it models human prostate carcinoma very closely. An anti-androgen drug resistant prostate cancer model was generated based on the VCaP cell line and is ideal for next generation discovery programs. In the OncoRat this model not only shows a great engraftment rate of nearly 100% but also clear regression and re-growth after castration as demonstrated in the figure.
VCaP-MDVR Tumor Kinetics in the SRG™ Rat
![VCaP-MDVR-graph](https://www.herabiolabs.com/storage/2023/07/VCaP-MDVR-graph.jpg)
VCaP-MDVR tumor growth in Hera’s SRG Rat.
Products & Services
![Xenograft Efficacy Studies – Hera Icon 051723](https://www.herabiolabs.com/storage/2023/05/Xenograft-Efficacy-Studies-Hera-Icon-051723.png)
Xenograft Efficacy Studies
Includes collection of blood, tissues & tumor for ADME, PK/PD and analysis.
![(Bi)weekly Tumor Sampling – Hera Icon 051723](https://www.herabiolabs.com/storage/2023/05/Biweekly-Tumor-Sampling-Hera-Icon-051723.png)
(Bi)weekly Tumor Sampling
Via fine needle aspiration (FNA). For longitudinal evaluation of drug exposure, histology and gene expression.
![OncoRats – Hera Icon 051723 – Hera Icon 051723](https://www.herabiolabs.com/storage/2023/05/OncoRats-Hera-Icon-051723-Hera-Icon-051723.png)
OncoRats
Cutting edge models optimized for engraftment.
Get help with your research by scheduling a call with Hera.
References
- 10.1039/c5mb00101c
- https://doi.org/10.1155/1998/298530
- https://doi.org/10.1371/journal.pone.0078398
- Rubin, I., and Yosef Yarden. “The basic biology of HER2.” Annals of oncology 12 (2001): S3-S8.
References MLA
- Ersahin, Tulin, et al. “The PI3K/AKT/Mtor Interactive Pathway.” Molecular BioSystems, 20 Apr. 2015, pubs.rsc.org/en/content/articlelanding/2015/MB/C5MB00101C.
- Fong, Jason T., et al. “Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and C-MET Inhibitor Resistance in Non-Small Cell Lung Cancer.” PLOS ONE, 4 Nov. 2013, journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0078398.
- Paterson, James W.E. “Brcal: A Review of Structure and Putative Functions.” Hindawi , 1998, www.hindawi.com/journals/dm/1998/298530/.
- Yarden, Rubin. “The Basic Biology of HER2.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2001, pubmed.ncbi.nlm.nih.gov/11521719/.